Table 1 Results of meta-analyses of GnRH analogs among patients treated for IVF – odds ratio of live birth rate
From: Optimal usage of the GnRH antagonists: a review of the literature
GnRH antagonists | GnRH agonists | Weight | Odds ratio (95% CI) | |||
|---|---|---|---|---|---|---|
Events | Total | Events | Total | |||
RCTs included in Kolibianakis et al. [23] | ||||||
Albano 2001 [25] | 34 | 198 | 19 | 95 | 0.83 (0.44-1.55) | |
European 2000 [8] | 97 | 486 | 61 | 244 | 0.75 (0.52–1.08) | |
Olivennes 2000 [26] | 22 | 126 | 9 | 43 | 0.80 (0.34–1.90) | |
N American 2001 [27] | 60 | 208 | 36 | 105 | 0.78 (0.47–1.28) | |
Middle East 2001 [28] | 72 | 236 | 37 | 119 | 0.97 (0.60–1.57) | |
Akman 2001 [29] | 4 | 24 | 5 | 24 | 0.76 (0.18–3.26) | |
Hohmann 2003 [30] | 18 | 111 | 10 | 58 | 0.93 (0.40–2.17) | |
Martinez 2003 [31] | 4 | 21 | 3 | 23 | 1.57 (0.31–8.01) | |
Franco 2003 [32] | 3 | 14 | 2 | 6 | 0.55 (0.07–4.56) | |
Hwang 2004 [33] | 8 | 27 | 8 | 29 | 1.11 (0.35–3.53) | |
Sauer 2004 [34] | 9 | 24 | 9 | 25 | 1.07 (0.33–3.41) | |
Loutradis 2004 [35] | 9 | 58 | 12 | 58 | 0.70 (0.27–1.63) | |
Check 2004 [36] | 8 | 30 | 5 | 30 | 1.82 (0.52–6.38) | |
Xavier 2005 [37] | 7 | 66 | 8 | 65 | 0.85 (0.29–2.48) | |
Malmusi 2005 [38] | 5 | 30 | 5 | 30 | 1.00 (0.28–3.89) | |
Marci 2005 [39] | 4 | 30 | 0 | 30 | 10.38 (0.53–201.45) | |
Cheung 2005 [40] | 3 | 33 | 2 | 33 | 1.55 (0.24–9.94) | |
Barmat 2005 [41] | 13 | 40 | 17 | 40 | 0.65 (0.26–1.62) | |
Bahceci 2005 [42] | 29 | 73 | 33 | 75 | 0.84 (0.44–1.61) | |
Badrawi 2005 [15] | 11 | 50 | 13 | 50 | 0.80 (0.32–2.02) | |
Schmidt 2005 [43] | 3 | 24 | 3 | 24 | 1.00 (0.18–5.53) | |
Lee 2005 [44] | 13 | 41 | 8 | 20 | 0.70 (0.23–2.11) | |
Total (n = 22) | 436 | 1950 | 305 | 1226 | 0 . 86 (0.72–1.02) | |
RCTs included in Al-Inany et al. [45] | ||||||
All women | ||||||
Albano 2000 [25] | 34 | 198 | 19 | 95 | 13.5% | 0.83 (0.44–1.55) |
Barmat 2005 [41] | 13 | 40 | 17 | 40 | 7.3% | 0.65 (0.26–1.62) |
Heijnen 2007 [46] | 70 | 205 | 78 | 199 | 33.0% | 0.80 (0.54–1.21) |
Hurine 2006 [47] | 17 | 91 | 17 | 91 | 8.8% | 1.00 (0.47–2.11) |
Kim 2009 [48] | 13 | 54 | 8 | 28 | 5.1% | 0.79 (0.28–2.22) |
Kurzawa 2008 [49] | 14 | 37 | 18 | 37 | 7.1% | 0.64 (0.25–1.62) |
Lin 2006 [50] | 22 | 60 | 21 | 60 | 8.4% | 1.08 (0.51–2.27) |
Marci 2005 [39] | 4 | 30 | 0 | 30 | 0.3% | 10.36 (0.53–201.45) |
Ye 2009 [51] | 35 | 109 | 39 | 111 | 16.6% | 0.87 (0.50–1.53) |
Subtotal (95% CI) | 824 | 691 | 100 . 0% | 0 . 86 (0.69–1 . 08) | ||
Total events | 222 | 217 | ||||
Heijnen 2007 [46] | 70 | 205 | 78 | 199 | 79.7% | 0.80 (0.54–1.21) |
Lin 2006 [50] | 22 | 60 | 21 | 60 | 8.4% | 1.08 (0.51–2.27) |
Subtotal (95% CI) | 265 | 259 | 100 . 0% | 0 . 89 (0.62–1 . 26) | ||
Total events | 97 | 102 | ||||
Heterogeneity: χ2 = 0.32, df = 1 (P = 0.57) | ||||||
Test for overall effect: Z = 0.66 (P = 0.51) | ||||||
Cetrorelix only | ||||||
Albano 2000 [25] | 34 | 198 | 19 | 95 | 26.3% | 0.83 (0.44–1.55) |
Hurine 2006 [47] | 17 | 91 | 17 | 91 | 17.1% | 1.00 (0.47–2.11) |
Kim 2009 [48] | 13 | 54 | 8 | 28 | 9.9% | 0.79 (0.28–2.22) |
Kurzawa 2008 [49] | 14 | 37 | 18 | 37 | 13.8% | 0.64 (0.25–1.62) |
Marci 2005 [39] | 4 | 30 | 0 | 30 | 0.5% | 10.36 (0.53–201.45) |
Ye 2009 [51] | 35 | 109 | 39 | 111 | 32.4% | 0.87 (0.50–1.53) |
Subtotal (95% CI) | 519 | 392 | 100 . 0% | 0.89 (0 . 65–1 . 23) | ||
Total events | 97 | 102 | ||||
Heterogeneity: χ2 = 3.31, df = 5 (P = 0.65) | ||||||
Test for overall effect: Z = 0.70 (P = 0.49) | ||||||
Ganirelix only | ||||||
Barmat 2005 [41] | 13 | 40 | 17 | 40 | 100.0% | 0.65 (0.26–1.62) |
Subtotal (95% CI) | 40 | 40 | 100 . 0% | 0 . 65 (0 . 26–1 . 62) | ||
Total events | 97 | 102 | ||||
Heterogeneity: not applicable | ||||||
Test for overall effect: Z = 0.70 (P = 0.36) | ||||||